GH Guardant Health, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Guardant Health, Inc. (GH) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 19, 2026, a 10-Q quarterly report filed on October 29, 2025, an 8-K current report filed on April 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Guardant Health, Inc. (GH) (SEC CIK 1576280), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
- • New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
Risk Factors
- • Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
- • Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
Management Discussion & Analysis
- • Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
- • Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • No new risk factors added this quarter; no material changes since fiscal 2024 10-K filing
- • Most materially updated risk: none reported, risk factors unchanged since 2024 10-K
Annual Reports Archive10-K
AI-powered analysis of Guardant Health, Inc. (GH) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Guardant Health, Inc. (GH) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $449.5M | $563.9M | $739.0M | $982.0M |
| Operating Income | -$544.4M | -$564.7M | -$443.6M | -$437.2M |
| Net Income | -$654.6M | -$479.4M | -$436.4M | -$416.3M |
| Op. Margin | -121.1% | -100.1% | -60.0% | -44.5% |
| Net Margin | -145.6% | -85.0% | -59.0% | -42.4% |
| Balance Sheet | ||||
| Total Assets | $1.6B | $1.8B | $1.5B | $2.0B |
| Equity | $60.2M | $158.7M | -$139.6M | -$99.3M |
| ROE | -1087.7% | -302.1% | 312.5% | 419.2% |
Source: XBRL financial data from Guardant Health, Inc. (GH) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 27, 2026 | — | — | — |
10-K | Feb 19, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 19, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Oct 29, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 30, 2025 | Jun 30, 2025 | — | |
10-Q | Apr 30, 2025 | Mar 31, 2025 | — | |
10-K | Feb 20, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 22, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 25, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest GH SEC filings in 2026?
Guardant Health, Inc. (GH) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did GH file its most recent 10-K annual report?
Guardant Health, Inc. (GH) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view GH 10-Q quarterly reports?
Guardant Health, Inc. (GH)'s most recent 10-Q quarterly report was filed on October 29, 2025. SignalX displays every GH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has GH filed recently?
Guardant Health, Inc. (GH)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find GH insider trading activity (Form 4)?
SignalX aggregates every GH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does GH file with the SEC?
Guardant Health, Inc. (GH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GH filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Guardant Health, Inc. (GH).
What is GH's SEC CIK number?
Guardant Health, Inc. (GH)'s SEC CIK (Central Index Key) number is 1576280. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1576280 to look up all GH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find GH return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Guardant Health, Inc. (GH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Guardant Health, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 30+ filings.